Berenberg Bank Boosts AstraZeneca (LON:AZN) Price Target to £145

AstraZeneca (LON:AZN) had its target price hoisted by Berenberg Bank from £142 to £145 in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s price target suggests a potential upside of 15.63% from the stock’s previous close.

A number of other research firms have also recently issued reports on AZN. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £110 target price on shares of AstraZeneca in a research note on Wednesday, July 30th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Monday, October 13th. Finally, Shore Capital reaffirmed a “buy” rating and issued a £145 target price on shares of AstraZeneca in a research note on Tuesday, October 7th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of £135.

AstraZeneca Trading Up 0.5%

AstraZeneca stock opened at £125.40 on Tuesday. The company has a market capitalization of £194.40 billion, a price-to-earnings ratio of 23.62, a PEG ratio of 0.86 and a beta of 0.17. The company’s fifty day moving average price is £119.85 and its two-hundred day moving average price is £110.18. AstraZeneca has a one year low of GBX 9,573.51 and a one year high of £129.72. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.

Insider Activity at AstraZeneca

In related news, insider Aradhana Sarin sold 9,563 shares of the company’s stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of £115.12, for a total transaction of £1,100,892.56. Insiders own 0.14% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.